FISHERS, IN / ACCESSWIRE / August 29, 2019 / American Resources Corporation (NASDAQ:AREC), a supplier of raw materials to the rapidly growing global infrastructure marketplace, with a primary focus on the extraction, processing, transportation and distribution of metallurgical coal to the steel industry, announced today that it will be presenting at the 4th annual RHK Disruptive Growth Conference in New York City on Wednesday, September 4 at 11:20 am ET. Chairman and CEO, Mark Jensen, CFO, Kirk Taylor and VP of Corporate Finance & Communications, Mark LaVerghetta will be presenting as well as meeting with investors.

The 2019 Disruptive Growth Conference will offer investors the opportunity to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy / alternative energy, healthcare, industrial, life science, natural resources, and technology.

For those interested in attending, please visit www.DisruptNYC.com for more information.

About American Resources Corporation

American Resources Corporation is a supplier of raw materials to the rapidly growing global infrastructure marketplace. The company’s primary focus is on the extraction, processing, transportation and selling of metallurgical coal and pulverized coal injection (PCI) to the steel industry. AREC’s operations are based in the Central Appalachian basin of eastern Kentucky and southern West Virginia, where premium quality metallurgical products are located.

The company’s business model is based on running a streamlined and efficient operation to economically extract and deliver resources to meet its customers’ demands. By running operations with low or no legacy costs, American Resources Corporation works to maximize margins for its investors while being able to scale its operations to meet the growth of the global infrastructure market.

Website:
http://www.americanresourcescorp.com

Institutional/Retail/Individual Contact:
PCG Advisory
Adam Holdsworth
646-862-4607
adamh@pcgadvisory.com
www.pcgadvisory.com

American Capital Ventures
Howard Gostfrand, President
305-918-7000 – Office
hg@amcapventures.com
www.amcapventures.com

Company Contact:
Mark LaVerghetta
317-855-9926 ext. 0
Vice President of Corporate Finance and Communications
investor@americanresourcescorp.com

About RHK Capital:

Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.

About TAG Group:

AGES as part of the holding company TAG Group, Inc., is a leading provider of estate, business and financial services for high net worth individuals and business entities. TAG maintains a comprehensive network of legal, financial and accounting professionals who are committed to providing the highest level of service to their clients. TAG maintains three separate and distinct operating units under its corporate umbrella, they are: Trust Advisory Group, Ltd., Advisory Group Equity Services, Ltd., and Estate Insurance Services, Ltd.

About Reed Smith:

Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. Our long-standing relationships and international outlook make us the go-to partner for speedy resolution of complex transactions, disputes and regulatory matters. At Reed Smith, we believe that the practice of law has the ability to drive progress. We know your time is valuable and your matters are important. We are focused on outcomes, are highly collaborative, and have deep industry insight that, when coupled with our local market knowledge, allows us to anticipate and address your needs. You deserve purposeful, highly engaged client service that drives progress for your business.

Special Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company’s actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond American Resources Corporation’s control. The words “believes”, “may”, “will”, “should”, “would”, “could”, “continue”, “seeks”, “anticipates”, “plans”, “expects”, “intends”, “estimates”, or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved.

SOURCE: American Resources Corporation

ReleaseID: 557855

LANSING, MI / ACCESSWIRE / August 29, 2019 / Andiamo Corporation (OTC PINK:ANDI) and its new management, in conjunction with the New Corporate Vision and Direction recently announced, is pleased to announce the Joint Venture Agreement with Wellington Center Pivot Farms (WCP). The Companies are excited to move forward together to farm Industrial Hemp on approximately 100 acres with harvests expected in the 4th Quarter, 2019.

“The Joint Venture with Wellington Center Pivot Farms is the first of several new business ventures planned for 2019,” stated Michael McDonald, CEO of Andiamo Corporation. “We are looking to either partner or acquire 3-5 additional companies within the hemp industry in 2019. We are working on bringing in companies we feel will work well within the mix.”

In additional news:

Since Mr. White is no longer with the Company, Andiamo Corporation is looking to relocate its headquarters to the Salt Lake City, Utah area. With the new direction, Andiamo will also be rebranding the company, marketing and websites. These changes will begin to take place in the month of September.

About Andiamo Corporation:

Andiamo Corporation, a Wyoming publicly traded company, is a dedicated partnership of multi-talented people striving to utilize the micro-cap world in the proper manner, with the goal of ensuring smaller companies in need of financing and direction have these resources available to them. We believe it is our duty to act responsibly and honestly to help ensure the success of our country’s greatest source of stability and job growth – the small business owner. In a realigning of our corporate focus and mission, we have transitioned from a one product company into a true source of developmental resources for other companies spread across a diverse range of industries. This rebranding of our culture and direction has enabled us to expand our role as a holding company, resulting in a marked increase in new business opportunities. Specifically, we look for established companies with recurring revenues who need a capital infusion to move their business to the next level of profitability. Follow us on Twitter @AndiamoCorp.

Safe Harbor:

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly revise any forward-looking statements.

Contact:
Andiamo Corporation
PR@AndiInc.us

SOURCE: Andiamo Corp.

ReleaseID: 557853

VAN NUYS, CA / ACCESSWIRE / August 29, 2019 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world’s leading clean technology manufacturer of microturbine energy systems, announced today that a lightning strike and associated gas leak forced the evacuation of approximately 60 households in a residential community of Tillsonburg, Ontario on Sunday, August 18th. Many of the residents were relocated into the Tillsonburg Community Centre which is powered by a Capstone microturbine combined heat and power (“CHP”) system installed by Vergent Power Solutions, Inc. (www.vergentpower.com), Capstone’s exclusive distributor for the Upper Midwest, New England and Eastern Canada.

According to the Woodstock Sentinel-Review, an Enbridge Gas spokesperson said that 125 homes were without gas while the repairs were completed. According to Enbridge, lightning struck a tree, traveling down through a root and damaged the natural gas pipeline. Emergency crews responded around 3 a.m. to a report of a lightning strike. Ontario Provincial Police (“OPP”) said the lightning ruptured the gas line, releasing a large amount of natural gas into several homes and underground sewer lines. Those forced to leave their homes were moved to the Tillsonburg Community Centre, the OPP confirmed.

Fortunately for the local residents, the Tillsonburg Community Centre (“TCC”), is powered by a Capstone microturbine CHP system that kept the facility’s electricity and hot water functioning despite the widespread power outage in the local area. The TCC was able to serve as a place of refuge for the small town.

According to OPP representatives, while there was some hesitation for people to leave their homes so early in the morning, the memory of a recent natural gas explosion in London’s Old East Village neighborhood was still fresh, so a lot of people moved quickly. The gas was shut off to a large area because of the potential for gas explosions. Thankfully, the gas leak was quickly remedied, and the community members were able to return home from the TCC.

“We are very proud that a Capstone CHP facility was the so-called port in the storm for so many residents of Tillsonburg,” stated Darren Jamison, Capstone’s President and Chief Executive Officer. “Utility power outages are becoming more commonplace as evidenced by recent wide-scale blackouts in New York and London and are becoming very commonplace in Capstone’s home state of California as we lead the country in power outages,” added Mr. Jamison.

According to the Eaton Blackout Tracker in 2017, 438 separate outage events caused by weather, falling trees, faulty equipment, human error, and others causes resulted in more than 25,000 minutes or 17 days of outages across California. The number of outages has been steadily increasing for the past decade and look to only continue as Pacific Gas & Electric instituted its first Public Safety Power Shutoff (PSPS) program by cutting power to approximately 22,700 customers in two events across five California counties, as wind speeds were forecast to accelerate.

“The shutoffs are designed as a proactive measure in times when there is a high risk of sparking a wildfire but can be very disruptive to utility customers and local business. The state regulators approved utility mitigation plans, including PSPS guidelines, several months ago,” added Mr. Jamison.

California is far from an outlier when it comes to power disruptions. Nationwide, there were more than 3,500 power outages in 2017, triggered by a surge in tornadoes, hurricanes, fires, floods, and other weather events. According to the U.S. Energy Information Administration, the duration of utility outages doubled between 2016 and 2017, again as a result of an increase in extreme weather events. The total cost to the American economy for the 2017 blackouts was estimated $150 billion.

“Today customers are not only looking to save money on energy costs and reduce carbon emissions with Capstone’s microturbine products, but resiliency solutions like the one at the Tillsonburg Community Centre are increasingly gaining momentum,” said Jim Crouse, Executive Vice President of Sales and Marketing. “The reliability of Capstone clean energy products, in some of the most remote and harsh environments in the world, makes Capstone a preferred solution for providing resiliency,” concluded Mr. Crouse.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world’s leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, providing scalable systems focusing on 30 kWs to 10 MWs that operate on a variety of gaseous or liquid fuels and are the ideal solution for today’s distributed power generation needs. To date, Capstone has shipped over 9,000 units to 73 countries and has saved customers an estimated $253 million in annual energy costs and 350,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, and YouTube.

Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as “expects,” “believes,” “objective,” “intend,” “targeted,” “plan” and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone’s filings with the Securities and Exchange Commission that may cause Capstone’s actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

“Capstone” and “Capstone Microturbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:

Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 557811

TORONTO, ON / ACCESSWIRE / August 29, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held September 8-10, 2019 in New York City.

Edesa Presentation Details

Date: Monday, September 9, 2019
Time: 2:35 pm Eastern Time
Location: Lotte New York Palace Hotel

Edesa senior management will be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with the company should contact conference coordinators to arrange an appointment or contact Edesa directly via email at investors@edesabiotech.com.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on efficiently developing innovative treatments that address significant unmet medical needs. Edesa’s lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis which has demonstrated statistically significant improvements in multiple clinical studies. Edesa’s investigational new drug (IND) application for EB01 was accepted by the FDA in November 2018. Edesa also intends to expand the utility of its sPLA2 inhibitor technology, which forms the basis for EB01, across multiple indications and expand its portfolio with assets that can drive long-term growth opportunities. The company is based in Markham, Ontario, Canada, with U.S. offices in Southern California.

Edesa Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “will,” “would,” “could,” “should,” “might,” “potential,” or “continue” and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa’s operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa’s product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa’s ability to protect its intellectual property and the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the company’s ability to control or predict. For a discussion of further risks and uncertainties related to Edesa’s business, please refer to Edesa’s public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

Contacts

Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800
investors@edesabiotech.com

SOURCE: Edesa Biotech

ReleaseID: 557785

NEW YORK, NY / ACCESSWIRE / August 29, 2019 / The traditional route post-college is either to find a job or to pursue a Master’s degree. Dallas Basha, on the other hand, decided to quit his job and drop out of his Master’s program following his college graduation. Today, Dallas operates and manages a multi-million dollar real estate company, Basha Real Estate, which he founded while in college.

Basha is also 24-years-old.

Before he emerged as Pennsylvania’s youngest real estate developer, Basha cut his teeth and learned the industry the hard way-by losing.

In 2015, Dallas Basha was a 21-year old student at Lehigh University with an insatiable taste for finance, real estate, and business development. By that time, he already had confronted his first real estate opportunity, which occurred two years before when he attempted to close a deal as a 19-year-old freshman that proved unsuccessful. What served as an opportunity to improve his negotiating skills and take his business acumen to the next level, Dallas decided to start a financial planning practice by partnering with Northwestern Mutual. In the two following back-to-back years, Dallas was awarded the top producer as a financial representative in the country.

With his financial planning success and earnings, Dallas eventually had a chance to buy a piece of undervalued land near his alma mater. He would soon after start an ambitious project in Pennsylvania’s South Bethlehem community to provide luxury housing for Lehigh University students.

While the project did eventually get off the ground, it only happened after several trips to the local historic board following numerous negotiations between Dallas and the committee.

The college town of South Bethlehem had a dearth of student apartment options. The alternative for off-campus housing includes 100-year-old rowhomes that most would consider poor-quality living conditions. Basha saw his latest real estate project as a perfect solution that not only would benefit the community but provide him a chance to prove his skills as a real estate developer.

Dallas leveraged his network and syndicated the deal by pooling investors to fund the development while taking full responsibility for managing the project. The 4-story student apartment complex is across the street from the campus hub – Farrington Square, which provides students the best of both worlds – luxury apartments in a stellar location.

Empowered by his latest achievement, Basha went on to acquire a historic building called the Grace Mansion (named after Eugene Grace, President of Bethlehem Steel), which he restored and converted to luxury apartments. At this point, Basha had already built a name for himself as the youngest real estate developer in Pennsylvania.

After graduating from college, Basha continued to advance in the fields of business and real estate. He soon quit his finance job and dropped out of his Master’s program to start his first two companies and to pursue his mission to “win by giving”, his self-coined term for winning in business while contributing to the community-at-large.

His first company, Basha Real Estate, builds long-term wealth for investors while improving communities through commercial investing. Some of his projects entail developing green buildings, renovating distressed properties, providing jobs to the local workforce, creating business opportunities in new retail spaces, improving curb appeal for neighborhoods, and creating new standards of living in low-income areas.

His second company, Southlight, is a student tailored real estate brand that redefines luxury living for off-campus housing at Lehigh University.

With two companies under his belt, and a portfolio worth millions, Basha’s empire is just getting started, but as with most empires, his wasn’t built in a day.

Have questions? Connect with Basha on Instagram @Dallasbasha, Facebook or email dallas@basharealestate.com

SOURCE: MentionWorth Media

ReleaseID: 557786

KUTAISSI, GEORGIA / ACCESSWIRE / August 29, 2019 / The problem with trading and acquiring cryptocurrencies is well known and always presents itself as follows:

“Where can I purchase crypto currencies safely, quickly, and easily, and above all, at a reasonable price?”

The practice turns out then with their answer mostly difficult, because users rely on several crypto currency exchanges to open a trading account, if you do not want to be ripped off. 1irstcoin has addressed this problem and innovatively solved it by applying an algorithm that scans the order books of the major crypto currency exchanges in fractions of a second while technically being able to provide our users with the crypto currencies of their choice decentralized and under a minimum of cost. In particular, we emphasize that this is a decentralized application. This means that we neither have to keep accounts for our users, or that we need to keep or accept FIAT or crypto-currencies of third parties, or hold them for third parties for the purpose of carrying out commissioned transactions. The user can carry out a so-called “single transaction” without having to open an account, or we are forced to carry out a registration. Only the payment processor carries out a so-called KYC and AML examination procedure in compliance with money laundering regulations. In any case, the user of our applications retains his assets under his own control and in his own possession.

Especially legal entities, as well as individuals, have often difficulty to finding access in cryptocurrencies. The methodology of banks and their doubters add to the rest, and in our view the progress and spread of cryptocurrencies is unstoppable. The benefits of investing in cryptocurrencies are obvious as they are readily available, tradable and exchangeable, with no opening hours 365 days a year. With over 120 different crypto currencies on offer, 1irstcoin is one of the world’s most innovative financial services companies in the new crypto industry.

In the first half of 2019, we were able to win over 20,000 new users for our applications. 1irstcoin is able to reach a four-digit growth this year and our company considered profitable from day one. The own crypto currency FST (1irst) is traded on various crypto currency exchanges and was able to achieve an ROI of over 800% in 2019 for our investors and owners.

We look forward to this incredible development with our users, owners and crypto currency traders, and see ourselves as part of renewing and adapting the entire financial market.

About 1irstcoin LLC:

1irstcoin LLC is a licensed financial services company under the legal and regulatory requirements of the Freezone Kutaisi in the Republic of Georgia. The company provides financial services and products in the cryptocurrency and Blockchain-Technologies segment. 1irstcoin LLC sees itself as an exclusive financial boutique in the era of Blockchain and wants to establish itself as one of the leading addresses for private and institutional investors with innovative financial products.

Kutaissi, the 29th of August 2019

CONTACT:

Peter Sommer
Director and Founder
1irstcoin LLC
More information under: https://www.1irstcoin.com

1irstcoin LLC
Free Industrial Zone
Avtomshenebeli 88
4600 Kutaissi
Republic of Georgia

Peter Sommer
Director 1irstcoin LLC

Investor Relation
Jenny Lam, Director Public Relation & Development
Email: info@1irstcoin.com

Additional features:
Picture: http://newsfeed2.eqs.com/firstcoin/865527.html

SOURCE: 1irstcoin LLC

ReleaseID: 557858

BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:

Citi 14th Annual Biotech Conference

Wednesday, September 4, 2019 at the Four Seasons Hotel in Boston. The Company will conduct one-on-one meetings with institutional investors at this conference.

Baird 2019 Global Healthcare Conference

Thursday, September 5, 2019 at 2:00PM EDT at the InterContinental New York Barclay Hotel in New York City. A webcast of the Company’s presentation will be available at this link.

H.C. Wainwright 21st Annual Global Investment Conference

Monday, September 9, 2019 at 9:10AM EDT at the Lotte New York Palace Hotel in New York City. A webcast of the Company’s presentation will be available at this link.

About Pieris Pharmaceuticals:

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases, immuno-oncology multi-specifics tailored for the tumor microenvironment, and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.

Forward Looking Statement:

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the expected timing of the reporting by the Company of key clinical data from its lead programs, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and co-development programs into and through the clinic and the expected timing for reporting data or making IND filings related to our programs, and partnering prospects for any such programs. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and the Company’s Quarterly Reports on Form 10-Q.

Company Contact:

Investor Relations Contact:

Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.

Dr. Allan Reine

Maria Kelman

SVP & Chief Financial Officer

Director of Investor Relations

+1 857 246 8998

+1 857 362 9635

reine@pieris.com

kelman@pieris.com

SOURCE: Pieris Pharmaceuticals, Inc.

ReleaseID: 557856

Flexpoint Sensor Systems Receives Purchase Orders as Sales Continue to Accelerate

DRAPER, UT / ACCESSWIRE / August 29, 2019 / Flexpoint Sensor Systems, Inc. (OTC PINK:FLXT) is pleased to announce it has recently received multiple, follow-on production orders from global market virtual reality leader, Manus VR. The orders, totaling nearly $40,000, are for a new production variation of their glove, allowing them to continue to be a market leader. Manus VR recently launched the brand new Manus Hand Mount, made to position the tracker on the hand, improving the native accuracy significantly. Using the new hand mounts removes the need for calibration, as well as drift. The sensors are expected to ship during the current quarter. As expected, the orders from Manus VR continue to grow in size and frequency.

Manus VR and their award-winning technology are at the forefront of this fast-growing industry. Manus VR is the world’s leading company for data gloves and is one of the few companies that measures the orientation of your hand, which allows full finger tracking. The glove is completely wireless and along with Flexpoint’s sensors, includes other technology partners. The product provides plugins for many of the major platforms. The Manus VR gloves bring solutions for VR simulations, motion capture, robotics and healthcare.

Established in 2016, Manus VR successfully brought to market a feature-rich glove offering. The glove integrates a number of technologies into a unique and truly inspired design. Manus VR has further realized their vision in supplying the industry’s finest components that integrate with various hardware platforms offered by such notable companies as HTC, Vicon, Xsens and others. Some of their more recent visionary partners include ESI Group and WorldViz.

“Flexpoint is proud to be fully integrated into the virtual reality product from a prestigious firm like Manus VR. These orders are important while we continue to work with several companies in other industries. We still anticipate larger orders across a variety of applications in the near term, but these orders with ongoing customers validate our technology. We continue to appreciate the long-term business partnership that is mutually beneficial. This relationship grows stronger as we continue to enhance and improve the technology. This reinforces our unique position in the rapidly evolving VR market,” stated Clark Mower, CEO Flexpoint Sensor Systems, Inc.

VR/AR will be an $80 billion market by 2025 according to Goldman Sachs. By comparison the TV market is $99 billion, the tablet PC market is $63 billion and the video game industry is $11 billion.

In addition to the gloves, Manus VR has developed a software development platform (SDK) that enables customers like those named above to design and build applications that extend far beyond virtual reality. This opens up a strong portion of the market that includes manufacturing, retail, healthcare, engineering, military and real estate applications.

Please visit http://www.flexpoint.com/ for more information or https://manus-vr.com/.

About Manus VR

The Manus VR glove will revolutionize the VR market. It is set to play a huge role in the virtual reality revolution. Manus VR believes in open innovation through sharing knowledge and experience. The possibilities of the Manus VR gloves are virtually endless and extend far beyond virtual reality.

In October 2014, Manus VR was selected from 10,000 candidates who took part in the Dutch StartupBootcamp HighTechXL, together with eleven other participants. The program helped Manus VR accelerate and build the business in just three months. After the program’s Demo Day in February 2015, the company signed up leading development partners and clients. Furthermore, it was fully funded at record speed, enabling the company to further develop the product.

Since developing the first working prototype in 2014, Manus VR has been a fast-growing company. It has grown around 300% and developed a functioning product in combination with a strong development platform.

About Flexpoint Sensor Systems, Inc.

Flexpoint Sensor Systems, Inc. (FLXT) is an innovative technology firm specializing in developing products that feature the Company’s patented Bend Sensor® and related technology. The Bend Sensor® is a groundbreaking sensing solution that is revolutionizing applications in the automotive, safety, medical and industrial industries. The Bend Sensor® single-layer, thin film construction cuts costs and mechanical bulk while introducing a range of functions and stylistic design possibilities that have never before been available in sensing technology. Flexpoint’s technology and expertise have been recognized by the world’s elite business and academic innovators for over 17 years. The company is setting a new standard for sensing solutions in the “smart” age of technology.

Forward-Looking Statements

This press release contains certain forward-looking statements. Investors are cautioned that certain statements in this release are “forward-looking statements” and involve both known and unknown risks, uncertainties and other factors. Such uncertainties include, among others, certain risks associated with the operation of the company described above. The Company’s actual results could differ materially from expected results.

Contact Information:

Flexpoint Sensor Systems
Clark Mower, President
801-568-5111

Brokers and Analysts
Chesapeake Group
410-825-3930

SOURCE: Flexpoint Sensor Systems, Inc.

ReleaseID: 557841

NEW HOPE, PA / ACCESSWIRE / August 29, 2019 / Iota Communications, Inc. (OTCQB:IOTC), a wireless network carrier and software service company providing Internet of Things solutions that optimize energy efficiency, sustainability and operations for commercial facilities announced today that it will be presenting at the 4th annual Disruptive Growth Conference being hosted by Reed Smith on September 5 in New York, NY.

Iota’s CEO & President, Terrence DeFranco, will be presenting, as well as meeting with investors and analysts. “Our business has gone through a significant transition over the past year and we are very excited about the direction and trajectory of our business in both the short and long term,” states Mr. DeFranco. “Our team is highly confident that we can execute on a very aggressive plan that will bring tremendous value to our stakeholders and we look forward to sharing this story with the investment community.”

Mr. DeFranco is scheduled to present on Thursday, September 5, 2019 at 3:20 pm EST.

For more information about the conference or to schedule a one-on-one meeting with Iota, please contact your RHK Capital representative or visit www.DisruptNYC.com.

About Iota Communications, Inc.

Iota is a leading IoT technology company that provides data-driven insights for sustainability enabled by our network connectivity, advanced analytics platform, and software-as-a-service solutions for commercial and industrial markets throughout the US. Iota also offers important ancillary products and services which facilitate the adoption of its subscription-based services, including solar energy, LED lighting, and HVAC implementation services. For more information, please visit our website at www.iotacommunications.com.

About RHK Capital:

Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.

About Reed Smith:

Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. Our long-standing relationships and international outlook make us the go-to partner for speedy resolution of complex transactions, disputes and regulatory matters. At Reed Smith, we believe that the practice of law has the ability to drive progress. We know your time is valuable and your matters are important. We are focused on outcomes, are highly collaborative, and have deep industry insight that, when coupled with our local market knowledge, allows us to anticipate and address your needs. You deserve purposeful, highly engaged client service that drives progress for your business.

Forward-Looking Statements:

This press release may contain “forward-looking statement” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include, but are not limited to, risks related to the acquisition and integration of the assets we acquired from Solbright Group, Inc., risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:

Iota Communications, Inc.
540 Union Square
New Hope, PA 18938
Attn: Investor Relations
investors@iotacommunications.com

Public Relations Contact:

Greg Lutowsky, SVP, Corporate Communications
glutowsky@iotacommunications.com
(855) 743-6478

SOURCE: Iota Communications, Inc.

ReleaseID: 557788

Preparing for Full Commercial Launch in September

REDWOOD CITY, CA / ACCESSWIRE / August 29, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported significant progress in the initial U.S. launch of the Pantheris SV (small vessel) image-guided atherectomy system. To date, physicians in 10 clinical centers have used Pantheris SV to successfully treat 50 patients in the U.S. Based on positive clinical reports and physician feedback from these initial sites, the Company is ramping production of Pantheris SV in preparation for full commercial launch, which is anticipated to begin in September.

Pantheris SV, a product line extension of Avinger’s onboard image-guided atherectomy platform, expands Avinger’s portfolio of atherectomy devices for the treatment of PAD and increases the number of addressable procedures for the Company’s Lumivascular technology by allowing physicians to target more distal regions of the vasculature in smaller diameter vessels. The device features a longer 140 cm catheter length and a smaller six French (6F) profile. During these first cases, physicians used Pantheris SV to successfully treat lesions within a variety of treatment scenarios in all of the major arteries between the knee and ankle, including the tibial-peroneal trunk, the anterior tibial, the posterior tibial, and peroneal.

Two of the first operators in the nation to use Pantheris SV, Dr. Jon George and Dr. Sean Janzer, interventional cardiologists from Einstein Medical Center in Philadelphia, provided comments on their initial experiences with the device. “I have now had the opportunity to use Pantheris SV in five cases,” said Dr. George. “Not only does this technology provide the excellent safety and efficacy that I have come to expect from Pantheris, I have also been very pleased with the ease of use, image clarity, and ability to treat an expanded set of target lesions. We were even able to prevent a possible amputation for one particular patient by treating areas in the foot that previously would have been difficult without imaging.”

Dr. Janzer noted, “Pantheris SV represents a significant step forward in the treatment of below-the-knee disease, an area of significant unmet clinical need. Other technologies have limitations in either their safety or efficacy profiles for treating these more challenging vessels. Through the combination of onboard image-guidance with directional atherectomy for targeted plaque removal and maximal luminal gain, I believe Pantheris SV offers the potential to deliver excellent long-term clinical outcomes for these patients.”

“We are very pleased with how rapidly physicians in the initial U.S. sites completed their first 50 cases with Pantheris SV and are even more excited about the acute clinical outcomes and positive physician feedback reported from the sites,” commented Jeff Soinski, Avinger’s President and CEO. “Based on this clinical experience, we are moving quickly to launch the remainder of our initial U.S. sites and are preparing to begin full commercial launch in September.”

Atherectomy is a minimally invasive treatment for PAD in which a catheter-based device is used to remove plaque from a blood vessel. Lumivascular technology allows physicians, for the first time ever, to see inside the artery during an atherectomy procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger’s proprietary Lightbox console. Physicians performing atherectomy with other devices must rely solely on X-ray images as well as tactile feedback to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, due to the real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation.

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our future performance, patient outcomes relating to Pantheris SV, our anticipated commercial launch and roll-out of Pantheris SV and other statements that are not historical facts. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; our ability to demonstrate the benefits of our Lumivascular platform; the resource requirements related to Pantheris; the outcome of clinical trial results; potential exposure to third-party product liability, intellectual property and other litigation; lack of long-term data demonstrating the safety and efficacy of our Lumivascular platform products; experiences of high-volume users of our products may lead to better patient outcomes than those of physicians that are less proficient; reliance on third-party vendors; dependency on physician adoption; reliance on key personnel; and requirements to obtain regulatory approval to commercialize our products; as well as the other risks described in the section entitled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2019 and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Public Relations Contact:

Phil Preuss
VP of Marketing & Business Operations
Avinger, Inc.
(650) 241-7942
pr@avinger.com

Investor Contact:

Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

SOURCE: Avinger, Inc.

ReleaseID: 557779